Ad
EXAS - Exact Sciences Corporation Stock Trading
About | Exact Sciences Corporation (NASDAQ:EXAS)
Not available
Quote | Exact Sciences Corporation (NASDAQ:EXAS)
| Last: | $65.66 |
|---|---|
| Change Percent: | 0.28% |
| Open: | $66.84 |
| Close: | $65.66 |
| High: | $67.2699 |
| Low: | $64.41 |
| Volume: | 1,349,177 |
| Last Trade Date Time: | 12/04/2023 03:00:00 am |
News | Exact Sciences Corporation (NASDAQ:EXAS)
-
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
-
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients PR Newswire Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence ...
Message Board Posts | Exact Sciences Corporation (NASDAQ:EXAS)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $EXAS News Article - Exact Sciences schedules first quarter 2023 earnings call | whytestocks | investorshangout | 04/10/2023 12:20:49 PM |
| znewcar1: $EXAS 24% v10,8M c58.82 f177,684M H60.93 gapNgo to HOD | znewcar1 | investorshangout | 01/09/2023 11:12:13 PM |
| whytestocks: $EXAS News Article - Medicare and Insurance Policy Updates in 2023 Will Improve Cancer | whytestocks | investorshangout | 12/20/2022 3:30:56 PM |
| $EXAS up big time in the pre-market. I've | OldAIMGuy | investorshub | 12/16/2022 1:37:32 PM |
| GH(-34%/AH)reports_results_of Shield ctDNA(liquid biopsy)diagnostic_for co | DewDiligence | investorshub | 12/16/2022 12:06:42 AM |
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
Ad
-
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients PR Newswire Updated TAILORx follow-up data showing the integration of clinico-pathologic criteria and Recurrence ...
-
Ark Invest’s Zoom Trade: On Wednesday, Cathie Wood-led Ark Invest made a significant move by purchasing over $12 million worth of Zoom Video ...